//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
In part 2 of our MASLD series, Sven Francque outlines that resmetirom is now approved in F2-F3 fibrosis in parts of Europe, semaglutide has produced positive phase 3 data in MASH, and the guideline is being updated. Tune in now: 🔗 https://bit.ly/44R97K3
We’ve explored how much of this burden is preventable – from the role of nutrition and ultra-processed foods 🍽️ to the life-saving potential of early detection through screening 🩺
This #DigestiveHealthMonth, we’ve taken a closer look at one of Europe’s most pressing public health challenges – the growing burden of digestive diseases and cancers 📊 – and what the evidence tells us about how to respond 👇
@alexsworking.bsky.social​ #DigestiveHealthMonth #EUNewsline
On #WDHD2026, listen to our recent policy webinar exploring whether the EU Safe Hearts Plan can improve digestive health – and the changes needed to drive progress on prevention. Watch the full discussion on YouTube: https://bit.ly/3Rb2vTx or Gutflix: https://bit.ly/4fn17Hi
Explore our dedicated #DigestiveHealthMonth page for insights and resources 👉 https://bit.ly/4iN57Ps #EUNewsline
#WDHD2026 marks a moment – but not the end of the conversation. What follows matters. Hear from @joostphdrenth.bsky.social​​ and Roos E. Pouw on what must happen next – ensuring evidence drives real change to reduce the burden of digestive diseases & cancers across Europe 🛡️
Thank you to everyone who joined us in Vienna for the joint meeting of National Societies Forum & Meeting of Members! From interactive workshop sessions to strategic exchanges – your engagement & insights are what drive the UEG community forward. Until next time! 💚 #weareUEG
🧬 Genetic testing does NOT replace surveillance in #PancreaticCancer Prospective study (n=500) 🔸 Pathogenic variants in 8.8%; 3.4% high-penetrance 🔸 ~50% carriers missed by current criteria 🔸 Cancer can occur without mutations Learn more in UEG Journal: 👉 https://bit.ly/4duoufq
UEG President Joost P.H. Drenth is at #EASLCongress 2026 to celebrate a truly outstanding congress – and to remind everyone: the GI and hepatology community will be back in Barcelona for #UEGWeek in October ➡️ https://ueg.eu/week @easlnews.bsky.social​ @joostphdrenth.bsky.social​